Saxagliptin

	WikiDoc Resources for Saxagliptin
Articles
Most recent articles on Saxagliptin Most cited articles on Saxagliptin Review articles on Saxagliptin Articles on Saxagliptin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Saxagliptin Images of Saxagliptin Photos of Saxagliptin Podcasts & MP3s on Saxagliptin Videos on Saxagliptin
Evidence Based Medicine
Cochrane Collaboration on Saxagliptin Bandolier on Saxagliptin TRIP on Saxagliptin
Clinical Trials
Ongoing Trials on Saxagliptin at Clinical Trials.gov Trial results on Saxagliptin Clinical Trials on Saxagliptin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Saxagliptin NICE Guidance on Saxagliptin NHS PRODIGY Guidance FDA on Saxagliptin CDC on Saxagliptin
Books
Books on Saxagliptin
News
Saxagliptin in the news Be alerted to news on Saxagliptin News trends on Saxagliptin
Commentary
Blogs on Saxagliptin
Definitions
Definitions of Saxagliptin
Patient Resources / Community
Patient resources on Saxagliptin Discussion groups on Saxagliptin Patient Handouts on Saxagliptin Directions to Hospitals Treating Saxagliptin Risk calculators and risk factors for Saxagliptin
Healthcare Provider Resources
Symptoms of Saxagliptin Causes & Risk Factors for Saxagliptin Diagnostic studies for Saxagliptin Treatment of Saxagliptin
Continuing Medical Education (CME)
CME Programs on Saxagliptin
International
Saxagliptin en Espanol Saxagliptin en Francais
Business
Saxagliptin in the Marketplace Patents on Saxagliptin
Experimental / Informatics
List of terms related to Saxagliptin

Saxagliptin
Identifiers
	IUPAC name (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl); acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;
CAS Number	361442-04-8;
PubChem CID	6451162;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H25N3O2
Molar mass	315.41 g/mol

Saxagliptin (rINN), previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.^[1] It was developed by Bristol-Myers Squibb. The trade name under which saxagliptin will be marketed has not yet been released.

It is currently in Phase III clinical trials in the U.S. and Europe for the treatment of type 2 diabetes mellitus.^[2]

Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP^[3] and the degradation of GLP-1.^[3]^[4]

Bristol-Myers Squibb announced on 27 December 2006 that Otsuka Pharmaceutical Co. has been granted exclusive rights to develop and commercialize the compound in Japan. Under the licensing agreement, Otsuka will be responsible for all development costs, but Bristol-Myers Squibb retains rights to co-promote saxagliptin with Otsuka in Japan.^[5] Further, on 11 January 2007 it was announced that Bristol-Myers Squibb and AstraZeneca would work together to complete development of the drug an in subsequent marketing.^[6]

References

↑ Augeri D; et al. (2005). "Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes". Journal of Medicinal Chemistry. 48 (15): 5025&ndash, 5037. PMID 16033281.
↑ "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". ClinicalTrials.gov (United States National Institutes of Health). 3 November 2006. Retrieved 2007-01-11. ClinicalTrials.gov Identifier: NCT00121641
↑ ^3.0 ^3.1 Mentlein, R (15 June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum". European Journal of Biochemistry. 214 (3): 829&ndash, 835. PMID 8100523. Unknown parameter |coauthors= ignored (help); |access-date= requires |url= (help)
↑ Ahrén, Bo (2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes". Journal of Clinical Endocrinology & Metabolism. 89 (5): 2078&ndash, 2084. PMID 15126524. Retrieved 2007-01-11. Unknown parameter |month= ignored (help); Unknown parameter |coauthors= ignored (help)
↑ "Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan" (Press release). Bristol-Myers Squibb. December 27, 2006. Retrieved 2006-12-27.
↑ Associated Press (11 January 2007). "AstraZeneca teams with Bristol-Myers on diabetes drugs". Delaware News-Journal. Retrieved 2007-01-11.

External links

Banting and Best Diabetes Centre at UT dp_iv
The race to get DPP-4 inhibitors to market - Forbes.com

Template:Oral hypoglycemics

Template:WikiDoc Sources

[ahren-1] Augeri D; et al. (2005). "Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes". Journal of Medicinal Chemistry. 48 (15): 5025&ndash, 5037. PMID 16033281.

[2] "Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". ClinicalTrials.gov (United States National Institutes of Health). 3 November 2006. Retrieved 2007-01-11. ClinicalTrials.gov Identifier: NCT00121641

[mentlein-3] 3.0 ^3.1 Mentlein, R (15 June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum". European Journal of Biochemistry. 214 (3): 829&ndash, 835. PMID 8100523. Unknown parameter |coauthors= ignored (help); |access-date= requires |url= (help)

[ahren2-4] Ahrén, Bo (2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes". Journal of Clinical Endocrinology & Metabolism. 89 (5): 2078&ndash, 2084. PMID 15126524. Retrieved 2007-01-11. Unknown parameter |month= ignored (help); Unknown parameter |coauthors= ignored (help)

[5] "Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan" (Press release). Bristol-Myers Squibb. December 27, 2006. Retrieved 2006-12-27.

[6] Associated Press (11 January 2007). "AstraZeneca teams with Bristol-Myers on diabetes drugs". Delaware News-Journal. Retrieved 2007-01-11.

[1]

[2]

[3]

[4]

[5]

[6]

Saxagliptin

See also

References

External links

Navigation menu

Identifiers

IUPAC name (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
CAS Number	361442-04-8
PubChem CID	6451162
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₈H₂₅N₃O₂
Molar mass	315.41 g/mol